Introducing the world’s only searchable, sortable database of cell and gene therapy manufacturing partners that is continuously updated.
A contract manufacturing organization (CMO) is a company that provides manufacturing services to cell and gene therapy companies on a contract basis. Contract development and manufacturing organizations (CDMOs) are similar, in that they offer services that include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
With the largest pandemic in modern history now underway, numerous cell and gene therapies are being explored for their potential use in the treatment and prevention of COVID-19.
Contract Manufacturing for Cell and Gene Therapies
Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise.
Benefits of partnering with a cell or gene therapy therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies.
Today, 50+ companies specialize in manufacturing and clinical trial support for cell and gene therapies (CGT).
In addition to industry giants that include Lonza, MaSTherCell S.A., WuXi, HCATS, and others, there are specialty CDMOs entering the CGT marketplace. For example, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
Anemocyte announced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. metres of GMP and GMP-compliant facilities for the production of ATMP’s, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies.
In other major news, industry behemoth Thermo Fisher Scientific snagged CGT CMO Brammer Bio for a price tag of $1.7 billion and Catalent Biologics acquired Paragon Bioservices for $1.2 billion.
Database of Cell and Gene Therapy CMOs / CDMOs
This database is the world’s only searchable, sortable database of cell and gene therapy manufacturing partners that is continuously updated on a daily basis.
Use it to identify potential manufacturing partners, or if you are a contract manufacturer, to identify the depth and breadth of your market competition.
This comprehensive database features:
- Name of company
- Description of cell and gene therapy manufacturing services
- Link to company’s CMO / CDMO services
Use it to:
1) Compare companies capable of manufacturing your cell or gene therapy product
2) Identify market competitors within the cell therapy CMO industry
3) Identify new market entrants offering CMO services
4) Spot countries with a high number of cell and gene therapy CMOs (“geographic hotspots”)
For a limited-time, you can claim this database for only $49 (40% off).
Act now and your product will be delivered instantly as an Excel download.
Of course, your investment is backed by a Greater than 100% Money Back Guarantee.